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Introduction. Elongation factor eEF1H is a multiprotein complex which comprises four functionally different subunits: eEF1A is responsible for delivery of correct aminoacyl-tRNA to the A site of 80S ribosome and supposedly facilitates the transport of deacylated tRNA back to aminoacyl-tRNA synthetase for recharging. Structurally different eEF1Ba and eEF1Bb apparently perform the same function to catalyze exchange of GDP for GTP in the eEF1A molecule, and the eEF1Bg subunit is believed to serve as a "glue" to keep all subunits of the eEF1B complex together [1, 2] .
Recent research has shown overexpression of the mRNA coding for the eEF1H individual subunits in different types of cancer [3] [4] [5] [6] . Despite this, there is 317 ISSN 1993-6842 . Biopolymers and cell. 2010. vol. 26 . N 4. Translated from Ukrainian Ó Institute of Molecular Biology and Genetics NAS of Ukraine, 2010 absolutely no information on how the amount of different eEF1H subunits in tissue depends on carcinogenesis. It is believed that the elongation factors are essential for the tumor functioning since the inhibition of polypeptide elongation reduced the tumor chemosensitivity [7] .
Previously we demonstrated the changes in the level of mRNA coding for eEF1H subunits in human glial tumors [8] . Glial tumors represent heterogeneous widespread (40%) intracranial group. Glioblastoma is the most aggressive tumor of human central nervous system with infiltrating ability.
Since the alteration of mRNA amount in tissues does not always correlate with a corresponding protein level we have analyzed whether the amount of eEF1H subunits changed in human glial tumors.
Materials and methods. Tissue samples. Glioblastoma samples (astrocytoma IV grade by WHO classification) were obtained from A.P. Romodanov Institute of Neurosurgery of Academy of Medical Sciences of Ukraine, Kyiv. The surgical samples of histologically normal brain tissue adjacent to a tumor were used as a conditionally normal tissue.
Isolation and purification of anti-eEF1A, -eEF1Ba, -eEF1Bb, -eEF1Bg antibodies. Rabbits were immunized with purified recombinant eEF1Bg (0.15 mg in 50% FCA (Sigma, USA) into six points intradermally on the back. The second injection was performed with the same amount of antigen in FCA 8 weeks later. After 2 months rabbits were boosted with 0.1 mg of antigen in 50% FIA (Sigma, USA).
Mice were immunized by intraperitoneal injection with 0.02 mg eEF1Ba or eEF1Bb in 50% FCA. Animals got the same doze of antigen in 50% FIA four weeks later. The last immunization was performed in 25 days. Rabbits or mice serum was removed in 8 days after the last immunization. The titer of antibody specificity in immunized animal serum was determined by ELISA assay.
Isolation of total immunoglobulin fraction was performed by ammonium sulfate precipitation with subsequent purification on DEAE-cellulose (Serva, Germany) and Protein-G Sepharose (Sigma, USA) according to the manufacturer's protocol.
The antibody specificity was checked by Western blot analysis against recombinant protein and human tissue extract of surgical samples using manufacturer's ECL-system protocol (Pierce, USA).
Western blot analysis. Frozen tissue samples were homogenized in liquid nitrogen and lysis buffer (10 mM K 2 HPO 4 pH 7.4, 100 mM NaCl, 1% NP-40, 1mM DTT, 0.1 mM PMSF), incubated in ice bath during 30 min and centrifuged 13000 g during 20 min at 4°C.
Protein concentration was assayed by Bradford's method [11] . The equal amount of each protein extract was resolved by 12% SDS-PAGE and transferred onto nitrocellulose membrane. The membrane was blocked in phosphate buffered saline (PBS: 1.47 mM K 2 HPO 4 , 4.29 mM Na 2 HPO 4 , 137 mM NaCl, 2.68 mM KCl, pH 7.3) containing 0.1% Tween-20 (PBS-T) and 5% powered milk for 1h, and incubated with primary antibody.
Mouse monoclonal anti-eEF1A (Upstate, USA), polyclonal anti-eEF1Ba and anti-eEF1Bb, and rabbit polyclonal anti-eEF1Bg were used to estimate a level of corresponding proteins in tissue extracts. After each ECL treatment, the membranes were stripped with PBS-T and re-probed with anti-b-actin antibodies (Santa Cruz, USA). Endogenous b-actin was used as a loading control. The densitometry analysis of signals was performed by the Scion Image program. Target protein expression was evaluated using the relative intensity ratio of target protein/loading control.
Results and discussion. Reactivity of polyclonal antibodies against subunits of eEF1B complex (eEF1Ba, eEF1Bb, eEF1Bg) with corresponding purified recombinant and endogenous proteins as well as the absence of recognition of nonspecific proteins in human tissue extracts were demonstrated using immunoblot technique (Fig. 1) .
Western blot analysis of eEF1A amount in glioblastoma as compared with normal samples did not show significant changes (Fig. 2) . Earlier we have not observe differences in the eEF1A mRNA expression in tumor and normal tissues [8] . The same situation has been found for eEF1Ba while the eEF1Bb mRNA level in glioblastoma is decreased. Though the total eEF1Bb mRNA amount in the tumor as well as in normal tissues is very low, a content of corresponding protein in investigated samples is readily detectable by Western blot analysis. The eEF1Bb amount was found to be equal in tumor and normal tissues (Fig. 2) .
The tendency of elevation of the eEF1Bg level in human glioblastoma (Fig. 2) was noticed. The interesting results concerning the eEF1Bg mRNA content have been found recently by us in human brain tumor [8] . Based on the stage disease analysis we have detected the increased eEF1Bg mRNA level in astrocytomas WHO grade II -III. However, the decreased eEF1Bg mRNA amount has been found in glioblastomas (astrocytoma WHO grade IV) as compared to normal tissue [8] . Thus, the current study does not demonstrate any correlation between changes in the eEF1Bg mRNA and protein in glioblastomas which suggests a possibility of post-translation regulation of the eEF1Bg level in this type of tumor.
An increased amount of mRNA coding for eEF1Bg was found in breast, gastric, colorectal and pancreatic tumors by other authors [12 -15] . In our study the first evidence of cancer-related increasing of eEF1Bg in glioblastoma has been obtained. The lack of coordinated changes in a level of other components of the complex may indicate the appearance of free eEF1Bg, which is not involved in the multisubunit complex in cancer cells. Summarizing our and literature data we hypothesize that eEF1Bg may possess other than translational function during carcinogenesis. For instance, eEF1Bg was reported to perform a specific function separately from the complex in the oxidative stress response [16] .
This report is the first attempt to study cancer-related changes in the amount of all components of the elongation translation factor eEF1H on the protein level. Unfortunately, restricted availability of the biological material did not allow us to investigate sufficient quantity of normal human brain samples for the classical statistical analysis. The changes in subunits level and tendency of increasing eEF1Bg amount in cancer will be investigated in further experiments with tumors of different localization.
Conclusions. The comparison of amount of different subunits of multiprotein elongation translation complex in human glioblastomas and normal brain tissue was performed using Western blot analysis.
The antibodies against eEF1Ba, eEF1Bb and eEF1Bg were obtained. No cancer-related changes in the amount of eEF1A, eEF1Ba and eEF1Bb were found except the tendency of increasing eEF1Bg amount in tumors.
The up-regulation of only one eEF1H subunit indicates that eEF1Bg might perform a separate cancer-related role besides its eEF1H-related translation function.
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